Lipids and diabetic nephropathy.
Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.
Rosario
Rey F
RF
Prabhakar
Sharma
S
D000804:Angiotensin II / Q000502:physiology; D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics; D003928:Diabetic Nephropathies / Q000453:epidemiology* / Q000503:physiopathology / Q000517:prevention & control; D004195:Disease Models, Animal; D018450:Disease Progression; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy; D017127:Glycation End Products, Advanced / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D012449:Safety
D001057:Apolipoproteins E; D017127:Glycation End Products, Advanced; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D000804:Angiotensin II